Integer Holdings Corporation stocks have been trading up by 20.96 percent after upbeat earnings guidance fueled investor optimism.
Click Here for a Millionaire's POV on Trading ITGR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Freedom Capital launched coverage with a Buy rating and a $112 price target, calling Integer a scaled, well‑positioned specialty CDMO and treating the expected 2026 dip as temporary.
- Truist raised its ITGR price target from $97 to $110 with a Buy rating, even as it flagged weak medtech volumes and muted capex across the sector.
- Citi lifted its target on Integer Holdings to $96 from $92, keeping a Neutral stance but flagging potential for a catch‑up trade in quality medtech names.
- Truist Securities highlighted an overweight analyst consensus on ITGR, with an average target around $99.44.
- The company scheduled its Q2 2026 earnings call, setting up a near‑term catalyst where it will share results and forward‑looking commentary.
Live Update At 16:46:59 EDT: On Friday, July 31, 2026 Integer Holdings Corporation stock [NYSE: ITGR] is trending up by 20.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Integer Holdings Corporation, ticker ITGR, just showed traders what a real breakout looks like. After grinding around the mid‑$90s for weeks, ITGR exploded from $100.87 at the open to close at $121.21, with a wild intraday spike to $123.50. That is a massive range for a typically calm medtech name and tells you fresh buyers are piling in.
On the 5‑minute chart, ITGR spent most of the day in a tight band near $100. Volume and volatility woke up sharply after 15:10, when the stock ripped from roughly $101 to the $120s in less than an hour. That is classic momentum‑shift price action.
Under the hood, ITGR is not a junk story. Revenue runs around $1.85B, growing high single to low double digits over three to five years. EBIT margin near 10.8% and EBITDA margin around 18.8% show a solid, profitable platform. The balance sheet is reasonable, with total debt to equity at 0.81 and a current ratio of 3.8, giving Integer room to ride out bumps.
More Breaking News
- Replimune (REPL) Jumps As FDA Panel Backs Melanoma Drug
- BMNR Stock Grinds Higher As Traders Watch Tight Range
- DNN Stock Drifts Lower As Uranium Traders Watch Key Support
- Western Union Stock Slides As Earnings Miss And Guidance Cut Rattle Traders
The trade‑off is valuation. A P/E around 34.5 and price‑to‑sales near 1.83 mean traders are paying up for quality and growth. In short, ITGR is acting like a momentum stock backed by real fundamentals.
Why Traders Are Watching ITGR Now
ITGR is suddenly front and center on many trading screens because the Street has turned up the volume. Freedom Capital kicked things off by initiating coverage of Integer Holdings with a Buy rating and a $112 price target. More than the number, the message matters: they see Integer as a scaled, well‑positioned specialty CDMO serving big medtech players and smaller OEMs, and they frame the expected 2026 sales and earnings dip as a temporary setback in a longer growth runway. That kind of language feeds a “buy the pullback” mindset among active traders.
Truist then reinforced the story, raising its ITGR target from $97 to $110 while sticking with a Buy rating in its Q2 MedTech preview. What stands out is that Truist did this while calling out skeptical sentiment, soft procedure volumes, and low capex across the sector. When analysts lift targets in a tough tape, it tells traders ITGR is viewed as a relative winner.
Citi played the more cautious role. It bumped the Integer Holdings target to $96 from $92 but stayed Neutral, saying ITGR may participate in a catch‑up trade as traders gravitate toward higher‑quality medtech names in a nervous Q2 earnings environment. That is not a slam‑dunk endorsement, yet it still adds to the upward pressure on expectations.
Truist Securities also pointed to an overweight consensus on ITGR, with a mean target around $99.44. With the stock now sprinting well above that zone, momentum traders will watch closely to see if the Street starts chasing higher or if this move stretches too far, too fast.
Conclusion
For active traders, ITGR now sits at the crossroads of fundamentals, sentiment, and timing. On the one hand, Integer Holdings is printing solid margins, steady revenue growth, and acceptable leverage. The company’s specialty CDMO positioning for large medtech clients gives ITGR a real business backbone, not just a story. On the other hand, the recent surge from the $90s to the $120s pushes the stock well above the current analyst mean target near $99.44, with Freedom Capital’s $112 and Truist’s $110 now acting more like reference points than ceilings.
The upcoming Q2 2026 earnings call is the next big catalyst. Integer Holdings has already set the schedule and access details, and traders will be listening for how management frames the anticipated 2026 dip versus the longer‑term growth arc. Any confirmation of “temporary slowdown, durable trajectory” can keep ITGR in play; any wobble in tone could trigger fast profit‑taking after this breakout. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” That lens is especially relevant here, with ITGR’s volume, price action, and earnings calendar all lining up—at least for now.
This is exactly the kind of setup Tim Sykes and the community study: strong news, sharp price expansion, and a clear catalyst on the calendar. As Sykes likes to say, “The pattern is the same, only the ticker changes.” For ITGR, the pattern right now is momentum built on rising analyst conviction. Traders just need to respect the risk, manage position size, and be ready to react when the next headline hits.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.